Matches 1 - 50 out of 106 1 2 3 >


Match Document Document Title
US20060051419 Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof  
An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.
US20050013861 Pharmaceutical excipient having improved compressibility  
A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient...
US20100272795 SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION  
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into...
US20090258066 COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS  
The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a weakly basic drug core, a layer of alkaline...
US20080248113 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with...
US20070190142 Dosage forms for the delivery of drugs of abuse and related methods  
A dosage form and method for the delivery of drugs, particularly drugs of abuse, characterized by resistance to solvent extraction, tampering, crushing, or grinding, and providing an initial burst...
US20070065512 MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE  
The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing...
US20070048378 Nanoparticulate anticonvulsant and immunosuppressive compositions  
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the...
US20060193914 Crush resistant delayed-release dosage forms  
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one...
US20140242162 PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN  
The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical...
US20120021053 CONTROLLED RELEASE AND TASTE-MASKING ORAL PHARMACEUTICAL COMPOSITION  
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,...
US20090028941 Pulsatile gastric retentive dosage forms  
Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent...
US20080260819 SUSTAINED RELEASE COMPOSITIONS OF DRUGS  
A sustained release pharmaceutical composition has been developed. The composition resists dose dumping when broken, crushed or chewed, which enhances the safety of the dosage form should it be...
US20070166368 Protein-Stabilized Liposomal Formulations of Pharmaceutical Agents  
The present invention relates to protein stabilized liposomes. Specifically, the present invention discloses compositions and methods for protein stabilized liposomes, the creation of protein...
US20070140975 Opioid formulations having reduced potential for abuse  
The invention provides opioid formulations having reduced potential for abuse, and having reduced potential for illegal sale and distribution. The opioid formulations of the invention comprise at...
US20050181049 Composition and method for enhancing bioavailability  
The present invention relates to compositions and methods for enhancing the bioavailability of beneficial agents with low water solubility.
US20050152975 Pharmaceutical composition  
The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a...
US20050063913 Novel metaxalone compositions  
The present invention is directed to nanoparticulate compositions comprising metaxalone. The metaxalone particles of the composition have an effective average particle size of less than about 2...
US20160038411 PULSATILE GASTRIC RETENTIVE DOSAGE FORMS  
Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent...
US20050147664 Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery  
The present invention is directed to compositions of one or more nanoparticulate active agents, at least one PEG-derivatized surface stabilizer, and at least one antibody or fragment thereof, and...
US20050074493 Extended release formulations of opioids and method of use thereof  
Extended release formulations for the delivery of opioid agonists, including oxycodone, are provided which exhibit low peak to trough plasma concentration fluctuations and sufficiently high plasma...
US20070003621 Dosage forms for movement disorder treatment  
The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug...
US20130108698 Enteric Coated Particles Containing An Active Ingredient  
Enterically coated particles and chewable tablets made therefrom are disclosed. The enterically coated particles are comprised of a core containing an active ingredient, a first coating layer...
US20060210622 Surface modified particulate compositions of biologically active substances  
This invention disclosure relates to compositions for the delivery of stable surface modified sub-micron and micron sized particles of water-insoluble biologically active substances from a...
US20050095293 Administration form for the oral application of poorly soluble drugs  
The invention relates to a new formulation for oral administration of active substances with pH-dependent solubility characteristics and the pharmacologically acceptable salts thereof, which...
US20050048116 Porous drug matrices and methods of manufacture thereof  
Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices...
US20050003003 Modulation of release from dry powder formulations  
Particles which include a bioactive agent are prepared to have a desired matrix transition temperature. Delivery of the particles via the pulmonary system results in modulation of drug release...
US20110150994 Modified Release Formulation  
The invention is directed to the use of an extended release tablet formulation for pramipexole.
US20100291204 COMBINATION OF A LONG-ACTING HYPNOTIC AGENT AND A SHORT-ACTING HYPNOTIC AGENT AND THERAPEUTIC USE THEREOF  
The invention relates to the combination of: a short-acting hypnotic agent which is selected from among a modulators of receptors GABA-A, a benzodiazepine, a phenothiazine, a melatonin derivative...
US20110008426 MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING MYCOPHENOLATE AND PROCESSES THEREOF  
Modified release pharmaceutical compositions comprising mycophenolate as the active agent or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or...
US20070003620 Morphine sulfate microgranules, method for preparing same and compositions containing same  
The present invention relates to sustained-release morphine sulfate microgranules each comprising a neutral support grain coated with an active layer and with a sustained-release layer, wherein...
US20060068010 Method for improving the bioavailability of orally delivered therapeutics  
The disclosed invention is a method and composition for improving the bioavailability of a pharmaceutically active ingredient comprising an oral dosage form consisting essentially of a granulation...
US20050058710 Porous drug matrices and methods of manufacture thereof  
Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices...
US20090238867 Nanoparticulate Anidulafungin Compositions and Methods for Making the Same  
Nanoparticulate compositions comprising anidulafungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections.
US20060233879 Controlled released dosage forms  
A zero-order release pharmaceutical dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A...
US20050181050 Dosage forms using drug-loaded ion exchange resins  
A multiparticulate, modified release composition for oral administration has been developed. The formulation is made by complexing a drug with an ion-exchange resin in the form of small particles,...
US20050181048 Compositions and methods for timed release of a water-soluble nutritional supplement, methylsulfonylmethane  
The present invention relates to compositions of and methods for producing timed or retarded release formulations that contain methylsulfonylmethane, C2-H6-O2-S and/or its dietary and...
US20050181047 Compositions and methods for timed release of water-soluble nutritional supplements  
The present invention relates to compositions of and methods for producing timed or retarded release formulations that contain glucosamine sulfate, beta-(1,4)-2-amino-2-deoxy-D-glucose, and...
US20060233880 Controlled release dosage forms  
A zero-order release pharmaceutical dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A...
US20060029670 Pharmaceutical Formulations and Method for Making  
The invention relates to a process of making an oral pharmaceutical formulation with variably adjustable release rate, which comprises one or more active ingredients, and one or more sucrose ester...
US20050106249 Once-a-day, oral, controlled-release, oxycodone dosage forms  
Oxycodone formulations are provided which produce substantially flat in vivo steady state plasma profiles. Tolerance levels associated with such profiles and tolerance levels associated with...
US20080187588 Formulations With Controlled Release Of Active Ingredient  
The present invention relates to novel pharmaceutical dosage forms with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable...
US20060159744 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof  
The present invention relates to timed dual release dosage forms of short acting hypnotics or salts thereof adapted to release the short acting hypnotic over a predetermined time period, according...
US20050169994 Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods  
The present invention also relates to carvedilol free base, salts, anhydrous forms, or solvates thereof, corresponding pharmaceutical compositions or controlled release formulations, and methods...
US20080031947 Orally dissolvable/disintegrable lyophilized dosage forms containing protected  
The present invention provides an orally dissolvable/disintegrable, lyophilized, dosage form adapted for direct oral dosing, including an active pharmaceutical ingredient ("API") containing...
US20060275367 Extended release formulations  
The present invention relates to an extended release formulation containing a poorly water soluble active ingredient and to a method for preparing the formulation. The formulation contains a...
US20060263429 Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof  
A compressible mixture prepared from a waxy filler, cellulose filler, or a mixture thereof and a disintegrant is disclosed for the preparation of compressed pharmaceutical compositions containing...
US20060159755 Method for producing a controlled release preparation  
The invention concerns a method for producing a controlled-release pharmaceutical preparation with a particle-containing coating, the coating being derived from an aqueous dispersion of a...
US20060121114 Method of manufacturing sustained release microbeads containing venlafaxine HCL  
A sustained release Venlafaxine composition that includes a plurality of non-agglomerated, uniformly-shaped and sized microbeads of inert core particles having a first coating layer. The first...
US20060073203 Dry polymer and lipid composition  
The present invention provides an orally administrable composition comprising a dry mixture of polymer, lipid and bioactive agent, being capable on contact with water or GI tract liquid of forming...

Matches 1 - 50 out of 106 1 2 3 >